Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–20. https://doi.org/10.1016/j.annonc.2022.07.004.
2. National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology (NCCN guidelines), gastric cancer (including cancer in the proximal 5 cm of the stomach) Fort Washington: NCCN; Available from: http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 6 February 2024.
3. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1.
4. Markar SR, Gronnier C, Pasquer A, et al. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study. Eur J Cancer. 2016;56:59–68. https://doi.org/10.1016/j.ejca.2015.11.024.
5. Gabriel E, Attwood K, Narayanan S, et al. Does neoadjuvant/perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma? J Surg Oncol. 2018;117(4):659–70. https://doi.org/10.1002/jso.24894.